The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Set up Biosimilar Dept. in October to Push Remicade Follow-On
September 21, 2016
- Eisai Looks to Achieve CAGR of 55% for Fycompa with Add’l Indications
September 20, 2016
- Ono, NCC Join Hands for Discovery of Anticancer Agents, Biomarker Research
September 20, 2016
- Osaka Univ. Spinoff, Sumitomo Dainippon Ink Joint Research Pact on Antibody-Inducing Peptides
September 20, 2016
- MSD, Kyorin to Copromote Nasonex Nasal Spray
September 16, 2016
- Asahi Kasei Pharma Gets Japan Rights to Basilea’s Antifungal Agent
September 16, 2016
- Lenvatinib Gets EU Nod for RCC: Eisai
September 16, 2016
- Sawai, Tatsumi Kagaku Tie Up on Kipres Generics
September 16, 2016
- Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache
September 14, 2016
- Takeda Returns Rights to MacroGenics’ RA Candidate MGD010
September 14, 2016
- Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
September 14, 2016
- “Regulatory Science Center” to Play Important Role to Establish Next-Generation Treatments: JPMA President
September 13, 2016
- Novartis Paid 13.2 Billion Yen to Doctors, Medical Institutions in 2015
September 13, 2016
- Nippon Shinyaku on Track to Achieve Targets in Midterm Plan with Sales of Selexipag Above Expectations: President
September 12, 2016
- Sales of Ethical Drugs Down 6.4% in July: Crecon Report
September 12, 2016
- Takeda Starts Global PIII for Dengue Vaccine
September 9, 2016
- Aspen Japan Launches Paxil AG
September 9, 2016
- Ono Files Kyprolis for Multiple Myeloma as Combo Therapy with Dexamethasone
September 8, 2016
- Ono Rolls out Multiple Myeloma Treatment Kyprolis
September 8, 2016
- Biogen Japan’s Hemophilia Spinoff to Be Up and Running in Early 2017
September 8, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…